Radiopharmaceutical · developed by Cellectar Biosciences
Iodine I 124 iopofosine is a radioconjugate of the radioisotope iodine I 124 attached to the alkylphospholipid ether analog iopofosine, intended for positron emission tomography imaging. It is taken up and retained by tumor cells, which accumulate it through lipid rafts and metabolize it poorly because of lower phospholipase-D activity. It is studied in multiple solid tumors and glioblastoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01898273 | Phase 2 | Glioblastoma | Terminated | CLRB |
| NCT01662284 | N/A | Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic… | Terminated | CLRB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Glioblastoma
Updated Oct 11, 2026. Something wrong or missing? Report it on the CLRB page.
See CLRB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CLRB catalysts and pipeline →